Especially, patients with genetic cardiomyopathies, including LMNA, RBM20, TTN subgroups or PLN, but also DCM related to chemotherapy or pregnancy are poorly responsive to classical HF therapies. This evidence concerns the gene LMNA and familial dilated cardiomyopathy.